Justification for IgE as a therapeutic target in chronic spontaneous urticaria.
TLDR
Monoclonal anti-IgE antibodies (omalizumab) are able to induce clinically significant benefits in patients with severe chronic spontaneous urticaria (CS), and a possible pathogenic role not previously supported for IgE and its receptors in this disease is considered.Abstract:
Summary Monoclonal anti-IgE antibodies (omalizumab) are able to induce clinically significant benefits in patients with severe chronic spontaneous urticaria (CS). Those results led clinicians and investigators to reconsider a possible pathogenic role not previously supported for IgE and its receptors in this disease, and to investigate additional approaches for understanding its pathogenesis. IgE antibodies to unknown environmental allergens able to trigger chronic urticaria are not generally regarded as the etiologic factor for the disease. Other proposed mechanisms for the production of wheals and angioedema in CSU include IgG autoantibodies and CD4-positive T cells directed to the high-affinity IgE receptor, autoantibodies to IgE itself, IgE autoantibodies directed to thyroid and nuclear autoantigens, highly cytokinergic IgE, and histamine-releasing factors able to bind to IgE and cause mast cell activation. It is expected that a better knowledge on the mechanisms leading to CSU and the clarification of the immunological effects of anti-IgE will provide novel therapies for this frequent condition.read more
Citations
More filters
Iconographies supplémentaires de l'article : Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy
Allen P. Kaplan,Dennis K. Ledford,Mark Ashby,Janice Canvin,James L. Zazzali,Edward Conner,Joachim Veith,Nikhil Kamath,Petra Staubach,Thilo Jakob,Robert G Stirling,Piotr Kuna,William E. Berger,Marcus Maurer,Karin Rosén +14 more
TL;DR: In this paper, the authors evaluated the safety and efficacy of 24 weeks of treatment with omalizumab in patients with persistent chronic idiopathic urticaria/chronic spontaneous urticria (CIU/CSU) despite treatment with H1-antihistamines, leukotriene receptor antagonists, or both.
Journal ArticleDOI
The pseudoallergen receptor MRGPRX2 on peripheral blood basophils and eosinophils: Expression and function
TL;DR: This work aimed to investigate whether human basophils and eosinophils express functional MRGPRX2, and found that they do not.
Journal ArticleDOI
Stress, pseudoallergens, autoimmunity, infection and inflammation in chronic spontaneous urticaria.
TL;DR: Effective treatment of CSU should involve the use of anti-histamines, intermittent steroids and anti-IgE therapy, and vitamin D3 supplementation, correction of intestinal dysbiosis and treatment of any chronic infection should also be considered.
Journal ArticleDOI
Total IgE as a Marker for Chronic Spontaneous Urticaria
Sabine Altrichter,Jie Shen Fok,Jie Shen Fok,Jie Shen Fok,Qingqing Jiao,Qingqing Jiao,Pavel Kolkhir,Pavel Kolkhir,Polina Pyatilova,Polina Pyatilova,Sherezade Moñino Romero,Jörg Scheffel,Frank Siebenhaar,Carolin Steinert,Carolin Steinert,Dorothea Terhorst-Molawi,Yi Kui Xiang,Martin K. Church,Marcus Maurer +18 more
TL;DR: The evidence in support of total immunoglobulin E (IgE) included in the diagnostic workup of patients with CSU has not yet been reviewed as mentioned in this paper, but the results of their review suggest that total IgE is a valuable marker for CSU, and they recommend its assessment in the routine diagnostic work-up of CSU patients.
Journal ArticleDOI
New biologics in the treatment of urticaria
Emek Kocatürk,Torsten Zuberbier +1 more
TL;DR: This review will focus on new biologics that are underway of production or are already under use for different disorders but could be beneficial for the treatment of Chronic urticaria.
References
More filters
Journal ArticleDOI
The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update.
Torsten Zuberbier,Werner Aberer,Riccardo Asero,Carsten Bindslev-Jensen,Zenon Brzoza,Giorgio Walter Canonica,Martin K. Church,Luis Felipe Ensina,Ana Giménez-Arnau,Kiran Godse,Margarida Gonçalo,Clive Grattan,Jacques Hébert,Michihiro Hide,Allen P. Kaplan,Alexander Kapp,A H Abdul Latiff,P. Mathelier-Fusade,Martin Metz,Alexander Nast,Sarbjit S. Saini,Mario Sánchez-Borges,Peter Schmid-Grendelmeier,F. E. R. Simons,Petra Staubach,Gordon Sussman,Elias Toubi,Gino A. Vena,Bettina Wedi,X J Zhu,Markus Maurer +30 more
TL;DR: This guideline covers the definition and classification of urticaria, taking into account the recent progress in identifying its causes, eliciting factors and pathomechanisms, and outlines evidence-based diagnostic and therapeutic approaches for the different subtypes ofUrticaria.
Journal ArticleDOI
Autoantibodies against the High-Affinity IgE Receptor as a Cause of Histamine Release in Chronic Urticaria
Michihiro Hide,D.M. Francis,Clive Grattan,John Hakimi,Jarema Peter Kochan,Malcolm W. Greaves +5 more
TL;DR: Histamine-releasing IgG autoantibodies against the alpha subunit of the high-affinity IgE receptor are present in the circulation of some patients with chronic urticaria.
Journal ArticleDOI
Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria
Marcus Maurer,Karin Rosén,Hsin-Ju Hsieh,Sarbjit S. Saini,Clive Grattan,Ana Giménez-Arnau,Sunil Agarwal,Ramona Doyle,Janice Canvin,Allen P. Kaplan,Thomas B. Casale +10 more
TL;DR: Omalizumab diminished clinical symptoms and signs of chronic idiopathic urticaria in patients who had remained symptomatic despite the use of approved doses of H-antihistamine therapy (licensed doses).
Journal Article
Identification of gamma-E-antibodies as a carrier of reaginic activity
TL;DR: Evidence was presented that reaginic antibody against antigen E in the serum of one individual was γE-globulin of mostly κ chain type, which is associated withReaginic activity of the final preparation was about 1000 times more active than the original sera and the most active fraction gave positive P-K reactions at a dilution of 1:80,000.
Iconographies supplémentaires de l'article : Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy
Allen P. Kaplan,Dennis K. Ledford,Mark Ashby,Janice Canvin,James L. Zazzali,Edward Conner,Joachim Veith,Nikhil Kamath,Petra Staubach,Thilo Jakob,Robert G Stirling,Piotr Kuna,William E. Berger,Marcus Maurer,Karin Rosén +14 more
TL;DR: In this paper, the authors evaluated the safety and efficacy of 24 weeks of treatment with omalizumab in patients with persistent chronic idiopathic urticaria/chronic spontaneous urticria (CIU/CSU) despite treatment with H1-antihistamines, leukotriene receptor antagonists, or both.